Precision Therapeutics announced today that a recent clinical study supporting the predictive value of the ChemoFx® chemoresponse assay in recurrent ovarian cancer was presented at the 2013 European Cancer Congress (ECCO-ESMO-ESTRO), held September 27 – October 1, 2013 in Amsterdam, Netherlands.
Help employers find you! Check out all the jobs and post your resume.
